Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
Rhea-AI Summary
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present at the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12, 2020, at 12:00 pm ET. A live webcast will be available on Curis' website in the Investors section, with a replay accessible for 90 days post-event.
Curis is advancing multiple cancer treatments, including drugs in collaboration with Aurigene and Genentech. Their pipeline includes CA-4948 for non-Hodgkin lymphoma and acute myeloid leukemia, with ongoing Phase 1 clinical trials.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CRIS
On the day this news was published, CRIS gained 8.18%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright & Co. 6th Annual Israel Conference on Thursday, November 12, 2020 at 12:00 pm ET.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright--co-6th-annual-israel-conference-301166177.html
SOURCE Curis, Inc.